AYLA · Old Ayala, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $91.0K | $38.0K | $458.0K | - | $625.0K | $761.0K | $974.0K | - | $845.0K |
| Cost of Revenue | - | $91.0K | $38.0K | $368.0K | - | $625.0K | $761.0K | $974.0K | - | $658.0K |
| Gross Profit | - | $0 | $0 | $90.0K | - | $0 | $0 | $0 | - | $360.0K |
| R&D | - | $7.20M | $5.58M | $7.50M | - | $7.37M | $8.12M | $6.92M | - | $5.42M |
| SG&A | - | $2.88M | $2.26M | $2.44M | - | $2.20M | $2.54M | $2.30M | - | $1.86M |
| Total Operating Expenses | - | - | - | $9.23M | - | - | - | - | - | - |
| D&A | - | - | - | $30.0K | - | - | - | $164.0K | - | - |
| Operating Income | - | ($10.08M) | ($7.84M) | ($9.85M) | - | ($9.57M) | ($10.66M) | ($9.23M) | - | ($7.28M) |
| Interest Expense | - | - | - | $3.0K | - | - | - | - | - | - |
| Income Tax | - | $106.0K | $214.0K | $189.0K | - | $167.0K | $162.0K | $248.0K | - | $115.0K |
| Net Income | - | ($10.19M) | ($8.21M) | ($10.03M) | - | ($9.80M) | ($10.84M) | ($9.57M) | - | ($7.44M) |
| EPS - Basic | - | ($0.68) | ($0.54) | ($0.74) | - | - | - | - | - | - |
| EPS - Diluted | - | ($0.68) | ($0.54) | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.41M | $11.20M | $20.06M | $27.05M | $36.98M | $40.84M | $44.41M | $56.03M | $42.02M | $48.75M |
| Accounts Receivable | $234.0K | $129.0K | $262.0K | $638.0K | - | $373.0K | $929.0K | $169.0K | $681.0K | $589.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.08M | $2.33M | $3.25M | $2.56M | $3.21M | $2.89M | $2.83M | $3.00M | $3.73M | $3.65M |
| Current Assets | $3.19M | $13.03M | $22.75M | $29.30M | $39.74M | $44.32M | $47.01M | $57.85M | $44.24M | $51.75M |
| Total Assets | $7.77M | $14.26M | $24.02M | $30.65M | $41.13M | $45.74M | $48.47M | $59.23M | $45.83M | $53.39M |
| Current Liabilities | $7.54M | $5.71M | $6.25M | $5.36M | $6.47M | $5.87M | $5.21M | $5.69M | $6.88M | $6.00M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | ($1.10M) | $8.16M | $17.36M | $24.82M | $34.16M | $39.38M | $42.76M | $53.03M | $38.40M | $46.93M |
| Retained Earnings | ($149.15M) | ($139.57M) | ($129.38M) | ($121.17M) | ($111.14M) | ($101.09M) | ($91.30M) | ($80.45M) | ($70.89M) | ($61.49M) |
Cash Flow
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($9.98M) | - | - | - | ($9.65M) | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | $0 | - | - |
| Financing Cash Flow | - | - | - | $44.0K | - | - | - | $23.64M | - | - |
| CapEx | - | - | - | - | - | - | - | $0 | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | ($9.65M) | - | - |
Ratios
| Metric | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | 0.0% | 0.0% | 19.7% | - | 0.0% | 0.0% | 0.0% | - | 42.6% |
| Operating margin | - | -11078.0% | -20631.6% | -2151.5% | - | -1530.6% | -1400.4% | -947.4% | - | -861.9% |
| EBITDA margin | - | - | - | -2145.0% | - | - | - | -930.6% | - | - |
| Net margin | - | -11195.6% | -21605.3% | -2189.3% | - | -1567.4% | -1424.6% | -982.3% | - | -880.2% |
| Free cash flow margin | - | - | - | - | - | - | - | -990.7% | - | - |
| FCF / Net income | - | - | - | - | - | - | - | 1.01 | - | - |
| R&D / Revenue | - | 7907.7% | 14684.2% | 1638.2% | - | 1178.9% | 1067.1% | 711.0% | - | 641.5% |
| SG&A / Revenue | - | 3170.3% | 5947.4% | 533.0% | - | 351.7% | 333.2% | 236.4% | - | 220.4% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -71.4% | -34.2% | -32.7% | - | -21.4% | -22.4% | -16.2% | - | -13.9% |
| Return on equity | - | -124.9% | -47.3% | -40.4% | - | -24.9% | -25.4% | -18.0% | - | -15.8% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.42 | 2.28 | 3.64 | 5.47 | 6.14 | 7.55 | 9.02 | 10.16 | 6.43 | 8.63 |
| Quick ratio | 0.42 | 2.28 | 3.64 | 5.47 | 6.14 | 7.55 | 9.02 | 10.16 | 6.43 | 8.63 |
| Cash ratio | 0.32 | 1.96 | 3.21 | 5.05 | 5.71 | 6.96 | 8.52 | 9.84 | 6.11 | 8.13 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | -3284.7x | - | - | - | - | - | - |
| Equity multiplier | -7.07 | 1.75 | 1.38 | 1.23 | 1.20 | 1.16 | 1.13 | 1.12 | 1.19 | 1.14 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | - | 0.01 | 0.00 | 0.01 | - | 0.01 | 0.02 | 0.02 | - | 0.02 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | 517d | 2517d | 508d | - | 218d | 446d | 63d | - | 254d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | 9330d | 31256d | 2543d | - | 1687d | 1359d | 1126d | - | 2022d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | -85.4% | -95.0% | -53.0% | - | -26.0% | -10.7% | -2.7% | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | -5.4% | 26.4% | -6.8% | - | -31.3% | -182.8% | -43.3% | - | - |
| Net income growth (YoY) | - | -4.0% | 24.3% | -4.8% | - | -31.7% | -61.5% | -45.0% | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | -50.5% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -79.3% | -59.4% | -53.2% | -11.0% | -16.1% | - | - | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Old Ayala against the 5 most active filers in the same SIC group.